en
svXspray Pharma’s Nomination Committee for the Annual General Meeting 2026
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting, May 12, 2026. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 13 May 2025, consists of: Thomas Eldered, appointed by Flerie AB, Chairman of the Nomination Committee Johan […]
Read moreXspray Pharma provides update on the FDA process for Dasynoc – observations at contract manufacturer delay approval
• FDA has issued a Complete Response Letter (CRL) regarding Xspray Pharma’s New Drug Application (NDA) for Dasynoc™, referring to GMP (Good Manufacturing Practice) observations at a contract manufacturer. These observations do not concern the Xspray´s production line. • Xspray discussed the product information for Dasynoc with the FDA up to the PDUFA date. The […]
Read moreNew number of shares and votes in Xspray Pharma after new share issue
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that the number of shares and votes in Xspray Pharma AB has changed. New shares have been issued as a result of the rights issue and over-allotment issue announced on August 15, 2025. On September 11, 2025, the Board of Directors also decided to increase the over-allotment […]
Read moreXspray’s rights issue oversubscribed – over-allotment issue increased and fully utilized
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read moreFirst day of trading in subscription rights and BTAs moved to August 27
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read moreXspray publishes disclosure document regarding rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read moreXspray receives additional subscription undertakings of SEK 20 million in the ongoing rights issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read moreXspray Pharma Submits XS003 to the FDA – The Company’s Second Product Candidate from the HyNap Platform
Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic myeloid leukemia (CML). The application is based on successful studies demonstrating bioequivalence with the reference product Tasigna®. XS003 demonstrates the lowest documented food interaction […]
Read moreInterim Report Second Quarter 2025
April–June 2025, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -44,885 thousand (-53,620) Earnings per share before dilution amounted to SEK -2.35 (-1.64) Cash flow from operating activities amounted to SEK -44,111 thousand (-64,181) Cash flow from investing activities amounted to SEK -6,132 thousand (-8,738) January–June 2025, Group […]
Read moreXspray resolves on a rights issue of approximately SEK 130 million with an over-allotment issue and carries out debt refinancing
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]
Read more